Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...
A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...
Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic ...
Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK ...
Daniel Ermann, MD, discusses a retrospective study he presented at the 2026 ASCO Annual Meeting that compared real-world ...
Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...
Daniel Ermann, MD, discusses what long-term clinical trial and real-world data have shown about the benefits and durability ...
TRIDENT is a global, open-label, two-arm trial; secondary end points include progression-free survival, overall radiologic ...
SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and ...
Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...
NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...
Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results